🇺🇸 FDA
Pipeline program

Nenocorilant 200 mg

CORT125236-750

Phase 2 small_molecule active

Quick answer

Nenocorilant 200 mg for Neoplasms is a Phase 2 program (small_molecule) at CORCEPT THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
CORCEPT THERAPEUTICS INC
Indication
Neoplasms
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials